Fate Therapeutics, Inc. (FATE)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 1.7M | 1.4M | 1.3M | 2.1M |
| Operating Income | (34.7M) | (34.7M) | (33.0M) | (31.1M) |
| Net Income | (32.2M) | (32.4M) | (31.2M) | (30.2M) |
| Diluted EPS | $-0.27 | $-0.27 | $-0.26 | $-0.25 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 96.3M | 63.5M | 13.6M | 6.6M |
| Operating Income | (308.4M) | (190.5M) | (195.5M) | (147.7M) |
| Net Income | (281.7M) | (160.9M) | (186.3M) | (136.3M) |
| Diluted EPS | $-2.91 | $-1.64 | $-1.64 | $-1.15 |